Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 6/20 | 0.65 |
| ▸ | MRGPRX4 | Q96LA9 | 10/20 | 0.62 |
| ▸ | RXRA | P19793 | 1/20 | 0.59 |
| ▸ | RXRB | P28702 | 1/20 | 0.59 |
| ▸ | RXRG | P48443 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | MITF | O75030 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | XBP1 | P17861 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.55 |
| ▸ | MGLL | Q99685 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22442364 | 1.00 | PTGER1 (0.65) | PTGER1MRGPRX4RXRARXRBRXRG | |
| SCHEMBL30719053 | 0.83 | MAPT (0.62) | PTGER1MRGPRX4RXRARXRBRXRG | |
| SCHEMBL26162596 | 0.82 | MRGPRX4 (0.76) | MRGPRX4RXRARXRBRXRGMEN1 | |
| SCHEMBL14413112 | 0.82 | PTGER1 (0.85) | PTGER1MRGPRX4CYP2C9 | |
| SCHEMBL20910307 | 0.81 | MGLL (0.65) | PTGER1NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL5096132 | 0.79 | PTGER1 (1.00) | PTGER1MRGPRX4RXRARXRBRXRG | |
| SCHEMBL2020761 | 0.79 | KMO (0.60) | RXRARXRBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22480793 | 0.77 | MRGPRX4 (1.00) | PTGER1MRGPRX4MEN1NPC1MITF | |
| SCHEMBL8675260 | 0.77 | PTGER1 (0.55) | PTGER1MRGPRX4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1568099 | 0.76 | MRGPRX4 (0.61) | PTGER1MRGPRX4RXRARXRBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | MAGI3, PYM1, MAG | PTGER1 1680/4885MRGPRX4 85/4885RXRA 4515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.